Gliclazide + Metformin Tablets(er) Generics - Manufacturers & Suppliers
Glizid-M XR(US & EU)
| Product/Composition:- | Gliclazide + Metformin Tablets(ER) |
|---|---|
| Strength:- | Gliclazide 30 mg/60 mg + Metformin 500/1000 mg |
| Form:- | Tablets(ER) |
| Reference Brands:- | Glizid-M XR(US & EU) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Gliclazide, a sulfonylurea, stimulates insulin secretion from pancreatic β-cells, while Metformin decreases hepatic glucose production and improves insulin sensitivity. This extended-release combination ensures stable blood glucose levels, reduces postprandial spikes, and improves patient adherence through once-daily dosing—offering synergistic control for type 2 diabetes with a lower risk of hypoglycemia.
Gliclazide + Metformin Extended-Release (ER) tablets are not FDA-approved in the United States but are widely authorized and marketed in the European Union under national procedures. The combination is indicated for managing type 2 diabetes mellitus in adults inadequately controlled on monotherapy. Products are registered under well-known brands like Diamicron MR + Metformin XR. European regulatory agencies mandate bioequivalence, stability, and pharmacodynamic evidence to ensure safety and efficacy. Although not listed in the U.S. Orange Book, this fixed-dose combination supports enhanced patient compliance and glycemic control. For sourcing support and B2B pharmaceutical trade, visit Pharmatradz.com.